Qualcomm Life Inc. and Novartis are expanding their global connected therapy management collaboration. Novartis will leverage Qualcomm Life's connectivity solutions to power its next-generation connected Breezhaler(TM), the inhaler for its Chronic Obstructive Pulmonary Disease (COPD) portfolio.

Novartis plans to launch the new connected Breezhaler in 2019 manufacturing, testing and regulatory approvals.